An Overview on Molecular Characterization of Thymic Tumors: Old and New Targets for Clinical Advances.

Abstract

Thymic tumors are a group of rare mediastinal malignancies that include three different histological subtypes with completely different clinical behavior: the thymic carcinomas, the thymomas, and the rarest thymic neuroendocrine tumors. Nowadays, few therapeutic options are available for relapsed and refractory thymic tumors after a first-line platinum-based chemotherapy. In the last years, the deepening of knowledge on thymus' biological characterization has opened possibilities for new treatment options. Several clinical trials have been conducted, the majority with disappointing results mainly due to inaccurate patient selection, but recently some encouraging results have been presented. In this review, we summarize the molecular alterations observed in thymic tumors, underlying the great biological differences among the different histology, and the promising targeted therapies for the future.

• Authors: Valentina Tateo, Lisa Manuzzi, Claudia Parisi, Andrea De Giglio, Davide Campana, Maria Abbondanza Pantaleo, Giuseppe Lamberti
• Journal: Pharmaceuticals (Basel, Switzerland) (Pharmaceuticals (Basel)) Vol. 14 Issue 4 (Apr 01 2021) ISSN: 1424-8247 [Print] Switzerland
• PMID: 33915954 (Publication Type: Journal Article, Review)